Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been ...

Sun Pharma inks exclusive licensing with LIB Therapeutics to commercialize lerodalcibep worldwide (excluding U.S. and China) ...

In den Vereinigten Staaten ist das Präparat als Lerochol durch die FDA zugelassen; diese Marke und der entsprechende Markt ...

Sun Pharmaceutical Industries and LIB Therapeutics Inc. announced an exclusive licensing agreement granting the Indian pharma ...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715; together with its subsidiaries and/or associated companies, "Sun Pharma") and LIB Therapeutics ...

Sun Pharma has entered an exclusive agreement with LIB Therapeutics to commercialise Lerodalcibep across markets outside the US and China, gaining access to a US$ 3.7 billion PCSK9 market.

LIB Therapeutics Inc. und Sun Pharmaceutical Industries Limited haben eine exklusive Lizenzvereinbarung bekannt gegeben, die ...

Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been obtained. The excluded China territory comprises mainland China, Hong Kong, ...

Pharma sector stocks such as Sun Pharma, Dr Reddy’s, Cipla, Biocon, Shilpa Medicare, Zydus Life and Hester Bio are in focus ...

Sun Pharmaceutical Industries Limited has announced an exclusive licensing, commercialization, and manufacturing agreement ...

Qualifying speciality medicines from India will be eligible for zero duty, providing some relief to Indian drugmakers with ...

See how Sun Pharma’s global lerodalcibep deal and EU-approved Lyrokaul expand LDL cholesterol treatment options outside the ...